Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Hematology
•
Vasculitis
•
ANCA Vasculitis
•
General Rheumatology
•
Nephrology
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
Negative TEE and malignancy work up.
Related Questions
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
How would you approach management of nodular scleritis in the setting of suspected GCA?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
Do you restrict topical diclofenac use in your patients with chronic kidney disease?
What is your approach to DVT prophylaxis in patients who require IVIG but are at increased risk for thrombotic events?
How do you approach the work up of pulmonary artery aneurysm in the absence of other clinical features of Behcet’s?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?